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1. Introduction 
Despite urologists increasingly employing more extended prostate biopsy schemes for 
initial biopsies, the rate of repeat biopsies continues to rise [1]. Advances in technology and 
improved understanding of prostate cancer have not eliminated the questions surrounding 
the issue of repeat biopsies. What are the most reliable indications for repeat biopsy? How 
many biopsy cores should be obtained for optimal diagnostic yield to reduce the incidence 
of false-negative biopsies? What areas of the prostate should be biopsied to give the best 
diagnostic results? What is the best time interval between repeat biopsies? To how many 
repeat biopsy sessions should a patient be subjected? 
Indications for repeat biopsy 
Indications for repeat biopsies include sustained or worsening elevation of total serum PSA 
or other PSA parameters. Repeat biopsy has more recently been incorporated as part of 
active surveillance protocols to monitor patients with low-risk disease for reclassification to 
aggressive disease. The histology from the initial biopsy may also encourage repeat biopsy if 
high grade prostatic intraepithelial neoplasia (HGPIN) or atypical small acinar proliferation 
(ASAP) are identified. Risk factors such as family history of prostate cancer and African 
American race have not been evaluated as potential indications for repeat biopsy but often 
impact urologists attitudes toward encouraging patients to undergo repeat biopsy. Patient 
anxiety about the possibility of prostate cancer is another common but difficult to quantitate 
indication for repeat biopsy.  
Prostate specific antigen as an indication for repeat biopsy  
An elevated or rising PSA level is the most common indication for repeat prostate 
biopsies. A PSA level over 4.0ng/ml is generally accepted as an indication for initial 
biopsy while some urologists will biopsy for a PSA over 2.5ng/ml or adjust the acceptable 
upper limit of normal PSA for the patient’s age. For repeat prostate biopsies after an 
initial set has been free of cancer, a PSA greater than 10.0ng/ml is agreed upon as a clear 
indication for the need for repeat biopsies while repeat biopsies are not felt to be strongly 
indicated for a PSA less than 4.0ng/ml [2-4]. PSA levels between 4.0 and 10.0 ng/ml 
present a significant range in which the indications for repeat biopsy are less obvious. 
Other PSA parameters can facilitate the decision to perform repeat biopsies. These include 
the percent-free PSA, PSA velocity (PSAV), PSA density (PSAD), and PSA density of the 
transition zone (PSAD-TZ).  
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Percent free PSA 
The majority of serum PSA is attached either alpha1-antichymotrypsin or alpha2-
macroglobulin. The remainder of the serum PSA that is not bound to these molecules is 
referred to as the “free” PSA and is decreased in the serum relative to the proportion of 
bound PSA in patients with cancer. The percentage of the total PSA (the bound and free PSA 
combined) that consists of the free PSA portion is termed the “percent free PSA.” The 
percent free PSA has good utility in predicting cancer presence, specifically in men with 
PSA levels of 4 to 10 ng/ml. Catalona et al. demonstrated percent free PSA cutoff of less 
than 25% corresponded with the highest cancer detection rate and the least number of 
unnecessary biopsies [5]. Djavan et al. recommend a percent free PSA of less than 30% as 
one of the most accurate predictors of a positive repeat biopsy result [2]. Morgan et al. 
demonstrated that a percent free PSA less than 10% was a strong predictor for prostate 
cancer on repeat biopsy even after two negative prior biopsies with sensitivity and 
specificity of 91 and 86%, respectively [6]. Lee et al. report percent free PSA less than 10% 
yielded 90% and 91% specificity in the one repeat biopsy and greater than one repeat biopsy 
groups, respectively (57). 
PSA density (PSAD) 
PSAD is calculated by dividing the PSA value by the prostatic volume. This calculation targets 
the problem of PSA elevation caused by benign prostatic hyperplasia and, when elevated, has 
been shown to correlate with the existence of cancer. Keetch et al. evaluated density to assist in 
determining the need for a repeat biopsy [7]. Using a value of 0.15 ng/ml/cm3, they reported 
missing 35% of the cancers. However, in conjunction with a PSAV>0.75 ng/ml/yr, they had a 
detection rate of 46% on repeat biopsy, vs only 13% when both values were below the 
suggested cutoff. Djavan et al. evaluated PSAD, but showed increased utility when it was 
related to transition zone volume only, known as the PSA density of the transition zone 
(PSAD-TZ) [2]. Using a value of 0.13 and 0.26 ng/ml/cc for PSAD and PSA-TZ, respectively, 
they report sensitivities of 74 and 78% and specificities of 44 and 52%, respectively. Calculating 
the PSAD-TZ has the potential for a high rate of error due to the need for high resolution 
ultrasound equipment and an experienced sonographer since the margins of the transition 
zone are not as clearly demarcated as those of the entire prostate [3].  
PSA velocity (PSAV) 
PSAV is determined by taking the difference between two PSA values and dividing by the 
time interval between the two levels in years. PSAV has found more utility as a tool to 
predict recurrence in patients already diagnosed with prostate cancer but has been 
employed as a predictor of biopsy outcome as well. In a comparison to other PSA 
parameters, Borboroglu et al found that a PSAV of greater than 0.75 ng/ml/yr was the only 
statistically significant risk factor for prostate cancer detection on biopsy [8]. However, the 
European Randomized Study of Screening for Prostate Cancer failed to show clinical utility 
for either PSA velocity or PSA doubling time [9]. Vickers et al. reported that prostate specific 
antigen velocity was statistically associated with cancer risk but had low predictive accuracy 
(AUC 0.55, p<0.001) (55). PSA doubling time (PSADT) is another measure of PSA change 
over time but has similarly demonstrated more utility in the prediction of prostate cancer 
aggressiveness than as an indication for repeat biopsy. 
Many investigators have now come to the conclusion that no single PSA parameter is 
adequate to indicate the need for repeat biopsies. Keetch et al. determined that using only 
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PSAV greater than 0.75 ng/ml/yr would miss a large number of cancers and recommended 
combining the PSAV other parameters [7]. Djavan et al. recommend the combination of a 
percent free PSA of less than 30% and/or a PSAD-TZ greater than or equal to 0.26 ng/ml/cc 
as the most accurate predictor of a positive repeat biopsy result in patients with PSA levels 
between 4 and 10 ng/ml [2]. Busby and Evans recommend a combination of total PSA, 
percent free PSA, PSAD, and PSAV based on analysis of the published data on each of these 
parameters [3]. Their recommended PSA-based indications for repeat biopsy include any 
patient with a PSA in the 4-10 ng/ml range and a percent free PSA less than 25%. For 
patients with a PSA between 4-10ng/ml and percent free greater than 25%, repeat biopsies 
are recommended if they have a PSAD greater than 0.15ng/ml/cc and a PSAV greater than 
0.75 ng/ml/yr, or a PSAV greater than 1 ng/ml/yr, or a PSAD-TZ  greater than 0.26 
ng/ml/yr. Both Djavan et al. and Busby and Evans recommend repeat biopsy in any patient 
with a PSA greater than 10 ng/ml, regardless of the other parameters. Busby and Evans 
qualify this recommendation by stating patients with PSA >10 ng/ml with inflammation 
noted histologically should have a trial of antibiotics and repeat PSA before considering 
repeat biopsy. 
Repeat biopsy for active surveillance protocols 
As PSA-based prostate cancer screening has expanded, some have noted the 
overdetection of cancer that would not have been detected in the absence of screening 
programs (51). The risks and benefits of invasive therapy for prostate cancer have been 
debated. Active surveillance (AS) has become established for low-risk patients to offset or 
delay the risks of invasive therapy. AS regimens monitor these low-risk patients via 
repeat prostate biopsies at fixed intervals to assess for those candidates with disease 
progression who should be offered radical treatment. The optimal parameters for timing 
of repeat prostate biopsy have not been definitively established (52). The European 
Randomised Study of Screening for Prostate Cancer (ERSPC) has instigated a prospective 
observational study, the Prostate Cancer Research International: Active Surveillance 
(PRIAS). This protocol includes a schedule for follow-up of low-risk prostate cancer 
patients that begins with a first repeat biopsy at 1 year after diagnosis. Bul et al. report 
that 21.5% of patients were reclassificatied to higher risk. This reclassification was 
significantly influenced by the number of initial positive cores, higher PSA density, and 
PSA doubling time (PSA-DT) < 3years (52).  
Van den Bergh et al. reports that PSAV and PSA-DT carry sparse evidence for their role as 
prognisticators, especially in active surveillance (53). They report some consensus of the 
unfavorable prognosis of PSA-DT < 3years and the favorable prognosis of PSA-DT > 10 
years or decreasing PSA level (53). The best method of calculation, number of 
measurements, and time interval of measurements remains unknown. 
Repeat biopsy for high grade prostatic intraepithelial neoplasia 
High Grade Prostatic Intraepithelial Neoplasia (HGPIN) is characterized by prostatic glands 
in which the epithelial cells exhibit the nuclear enlargement and prominent nucleoli 
characteristic of prostatic adenocarcinoma, yet with a preserved basal cell layer. While the 
presence of a basal cell layer excludes the diagnosis of invasive cancer, HGPIN is thought to 
be a precursor to invasive adenocarcinoma [10]. Evaluating pathology trends on 62,537 
initial prostate needle core biopsies submitted by office-based urologists, processed at a 
single pathology laboratory, isolated high grade PIN was diagnosed in 4.1% of the biopsies 
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[11]. In a referral academic practice employing extended field biopsies for initial prostate 
tissue sampling, 22% of cases exhibited isolated HGPIN [12].  
After sextant biopsies showing HGPIN, 80% of patients demonstrated cancer on repeat 
biopsy [13]. With extended biopsy schemes showing HGPIN, the rate of cancer detection on 
repeat biopsies was only 23% [14]. This decreased cancer detection rate after extended 
biopsy schemes is probably due to the better sampling and increased likelihood of 
identifying co-existing cancer and HGPIN on the initial extended biopsy procedure.  
Low grade prostatic intraepithelial neoplasia does not carry the same risk of concomitant 
cancer. Zlotta et al. found that low grade PIN was associated with subsequent cancer on 
repeat biopsies in  10.7% of patients with a PSA was between 4 and 10ng/ml and in none of 
the cases when PSA was ≤4ng/ml [15]. Low grade PIN is not considered an indication for 
repeat biopsy unless other factors such as an elevated PSA increase the suspicion of prostate 
cancer. In fact, the notation of the presence of low grade PIN has been discouraged from 
being mentioned in pathology reports. 
Most experts strongly recommend repeat biopsy for any patient with HGPIN on initial 
biopsy [3,16]. If HGPIN is again identified on repeat biopsy but no cancer diagnosed, 
follow-up PSA and examination in 6 months is recommended.  
Repeat biopsy for atypical small acinar proliferation  
Atypical Small Acinar Proliferation (ASAP) is a focus of small glands that have the cytologic 
appearance of malignancy; however, the presence or absence of the basal cell 
layer is equivocal [17]. Rather than a pre-malignant lesion, this finding is felt to often 
represent invasive cancer that is simply difficult for the pathologist to clearly identify due to 
issues such the plane of sectioning. In patients with ASAP, cancer found on repeat biopsy is 
most likely to be in the same region of the prostate as was the ASAP. Repeat biopsy samples 
in patients with ASAP are found to have cancer in approximately 40–50% of cases [13]. Zhou 
et al. affirmed these findings with the report that of patients diagnosed with ASAP, 51.0%  
were diagnosed with prostate cancer on repeat biopsy (56). This rate has not changed in the 
era of extended biopsy schemes.  
ASAP is considered an absolute indication for repeat biopsy [3,16]. Negative repeat biopsies 
require close follow-up. 
Impact of prostate volume on repeat biopsies 
Prostate volume is an important parameter when deciding whether or not to perform a 
repeat biopsy. Rietbergen et al. found that the most important factor responsible for failure 
to diagnose these cancers at the primary screening was a large prostate volume in the 
European Randomized Study for Screening for Prostate Cancer [18]. One explanation is the 
possibility that these patients’ increased PSA levels are primarily due to the volume of 
prostatic hyperplasia. The lower biopsy yield in larger prostates has also been attributed to 
undersampling since a proportionally smaller amount of tissue is sampled relative to the 
total prostate volume. The potential for undersampling in large prostates is compounded by 
the fact that larger glands tend to harbor smaller volume tumors [19].  
Remzi et al. showed that there were increased numbers of cancers discovered on repeat 
biopsy for those with prostate volume 20-80 cc and for those whose TZ volume was 9-40 cc 
[20]. Beyond these size limits, they discourage repeat biopsy unless there is very strong 
suspicion of cancer based on other characteristics. Basillote et al. also demonstrated 
increased false-negative rates in patients with increased prostate volumes [21]. Using 
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extended biopsy schemes for initial biopsies, Ung et al. found no increased prostate cancer 
detection rates in larger volume prostates [22]. However, Sajadi et al found a much lower 
cancer detection rate with repeat “saturation” biopsies in large prostates compared to 
smaller glands (57% positive biopsy rate in glands less than 37cc and only 7% for larger 
glands) [23].  
In practical terms, large prostates can often result in an initial biopsy that shows no 
malignancy. At least one set of repeat, extended biopsy of moderately enlarged prostates in 
patients with persistent concern about cancer appear justified. For extremely enlarged 
prostates (over 80 cc) the utility of repeat biopsies is unclear. 
Repeat biopsies and inflammation 
Prostatic inflammation often causes an increase in serum PSA levels. While the pathogenesis 
of inflammation-related PSA elevation is not completely understood, it is theorized to result 
from either leakage of PSA from epithelial cells into the serum or through stimulation of 
PSA production by epithelial cells through inflammatory-mediated substances  [24, 25]. 
Nadler et al. noted that prostate inflammation and volume were the most important factors 
resulting in PSA elevations in those without prostate cancer [26]. Okada et al. found that 
histologically evident acute inflammation was the only independent determinant of serum 
PSA in those with prostates smaller than 25 cc [24]. While inflammation may inflate total 
PSA, it does not appear to influence the percent-free PSA [27]. To further complicate 
matters, we have demonstrated that the histologic finding of inflammation increases with 
sequential repeat biopsies [1]. Abouassaly et al have shown that the presence of 
inflammation can increase likelihood of the histologic diagnosis of ASAP, creating another 
avenue by which inflammation can stimulate the performance of unnecessary repeat 
biopsies [28]. Although it has not been clinically validated, interval antibiotic administration 
to correct PSA elevation secondary to histologic inflammation may help PSA reach its true 
baseline [3]. 
Time interval to repeat biopsies 
Patients at high risk for existing cancer should undergo repeat biopsy without delay, 
recommendations vary between 2 and 6 weeks [2, 3]. High risk patients include those with 
ASAP or HGPIN. Others fitting this high-risk category include patients without 
inflammation on initial biopsy whose PSA is >10 ng/ml or with both a PSA between 4 and 
10 ng/ml and percent free <10%. Other risk factors such as family history of prostate cancer 
and African American race have not been studied in relationship to the interval between 
initial and repeat prostate biopsies. 
For patients who are not at high risk, a repeat PSA in 3 to 6 months to allow for calculation 
of PSAV has been recommended. While many patients will be relieved to postpone repeat 
biopsy for a few months, many will find the wait very anxiety-provoking. There is certainly 
no contraindication to more expeditious repeat biopsy in a very anxious patient.  
Patient preparation 
Patient preparation for repeat biopsies is a duplicate of the preparation used for initial 
biopsy in many facilities. Most urologists have the patient give themselves an enema before 
the procedure [29]. While taking aspirin or non-steroidal anti-inflammatory drugs is not an 
absolute contraindication to prostate biopsy, avoiding these medications for at least 10 days 
prior to the procedure is preferable. Some of the more aggressive extended biopsy schemes 
are performed under general anesthesia or with monitored sedation. Without the systemic 
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control of discomfort, periprostatic injection of local anesthetic is strongly recommended 
before subjecting an patient to extended biopsy schemes [30].  
A short course of an oral fluoroquinolone antibiotic is the most common preparation [29]. 
Since these patients have already had a course of antibiotics for their prior biopsy and may 
have taken an even longer course of antibiotics if treated for prostatic inflammation, the 
possibility of resistant bacteria should be considered [31]. Pre-procedure urine culture, 
extended oral antibiotic coverage, or additional prophylaxis with an intravenous or 
intramuscular injection of an aminoglycoside should be considered.  
Location and number of repeat biopsy cores 
Hong et al. demonstrated that prostate cancer detection rates on repeat biopsy vary as a 
function of the extent of the initial biopsy [32]. If the prior negative biopsy was a sextant 
scheme, the cancer detection rate was 39% with a repeat extended biopsy, whereas if the 
prior negative biopsy was an extended scheme, the cancer detection rate was 28%. In 
general, areas not sampled on initial biopsy have higher rates of cancer detection when 
those areas were sampled on repeat biopsies. Therefore, repeat biopsy schemes typically 
consist of extended biopsy schemes designed to sample the areas of the prostate 
incompletely sampled by the initial biopsy. Repeat biopsy techniques also target those 
anatomic areas of the prostate where malignancy is more likely to reside. Repeat extended 
biopsy schemes consist of the classic sextant biopsy pattern plus various combinations of 
anteriorly directed biopsies that are designed to sample the transition zone,  posterolateral 
sampling which includes the anterior horn of the peripheral zone, and anterior apical 
biopsies. 
Directed biopsies 
Directed biopsies were the initial approached used in conjunction with prostate ultrasound 
for prostatic sampling. With this approach, biopsies are taken only from areas that were 
suspicious on the ultrasound images and/or digital rectal examination. This method was far 
superior to the previously utilized digitally directed "blind" biopsies, however, with the 
current predominance of non-palpable isoechoic prostate tumors, biopsy sites limited to 
either sonographically hypoechoic lesions or areas of palpable abnormality have limited 
utility [1]. Most current extended biopsy schemes include any region in which an 
abnormality-directed biopsy would sample but an occasional directed biopsy in conjunction 
with the performance of an extended biopsy scheme may be useful in selected patients. . In 
addition, patients with ASAP should have additional cores obtained from the region of the 
ASAP [14]. This is in contrast to patients who are found to have HGPIN, where the finding 
of cancer on repeat biopsy is equally likely throughout the gland [14]. Some investigators 
have found a slight increase in cancer detection rates on repeat biopsies in the area from 
which the original biopsy containing HGPIN was taken [33,34]. These authors recommend 
that additional biopsies should be performed in the area previously harboring HGPIN. 
Sextant biopsies 
The sextant biopsy scheme, a method of obtaining spatially separated biopsies from each 
sextant of the prostate, was designed to improve the odds of sampling clinically inapparent 
tumors. These biopsy sites were originally described in mid-lobe parasagittal plane at the 
apex, mid-gland and base bilaterally. Although far superior to directed biopsies, sextant 
biopsies maintain a false negative rate between 15% and 34% based on repeated biopsies 
and computer simulations [1]. While sufficient for histologic confirmation of the presence of 
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cancer in patients with very abnormal digital rectal examinations and elevated PSA levels, 
use of sextant biopsies alone is generally considered inadequate for routine initial or repeat 
biopsies [2,3,16]. “Extended” biopsy is the terminology typically used to refer to greater than 
six biopsy cores taken in the sextant fashion. Despite falling out of favor as the sole 
approach to prostate sampling, sextant biopsies in conjunction with additional biopsies as 
part of an extended biopsy scheme continue to contribute significantly to the successful 
detection of prostate cancer [35]. 
Lateral biopsies 
Pathologic analysis of radical prostatectomy specimens suggests that small prostate cancers 
occur in the posterolateral portion of the gland. These cancers are still in the peripheral zone 
where most prostate cancers reside, but are in the portion of the transition zone that wraps 
anteriorly and laterally. This area is occasionally termed the “anterior horn” in the literature. 
Stamey initially described the concept of targeting this area of the prostate with laterally 
placed sextant biopsies [36]. Eskew et al. introduced the first extended biopsy scheme for 
routine cancer detection and included the use of lateral biopsies [37]. The 5 regions included 
the standard sextant biopsies in the mid-lobe parasaggital plane bilaterally as well as two 
biopsies from lateral aspect of the prostate and three biopsies from the midline. Of the 119 
patients studied, 48 (40%) were found to have prostate cancer on the biopsy, of which 17 (35% 
of cancers identified) were only detected in the additional non-sextant sites. Through analysis 
of the cancer detection yield of each individual biopsy site, Presti et al. first popularized the 10-
core biopsy scheme combining routine mid-lobar sextant biopsies plus lateral biopsies on each 
side for routine use in all patients [38]. This technique perfected the concept of extended 
biopsies proposed by Eskew et al by determining the number and location of biopsies that 
resulted in the maximum cancer detection rate for the minimum number of biopsies 
performed. Lateral biopsies of the peripheral zone at the base and mid gland were added to 
the routine sextant biopsy regimen for a total of 10 systematic biopsies of the peripheral zone. 
Mian et al. utilized a 10-biopsy schema including the six sextant biopsies and two biopsies 
from each of the anterior horns of the peripheral zone [39]. This resulted in cancer detection in 
33% of initial biopsies in 939 men. Babaian et al first introduced the use of extended biopsy 
schemes for repeat biopsies in 278 patients with prior negative prostate biopsies [40]. This 11-
core strategy included sextant, lateral and anterior transition zone biopsies bilaterally.  
Transition zone biopsies 
We initially introduced the biopsy technique to sample the anterior prostate, or transition 
zone, in order to evaluate patients with cancer diagnosed by transurethral resection of the 
prostate (TURP) for residual/recurrent disease [41]. Anterior biopsies detected residual 
cancer in 47% of patients in whom cancer was detected by TURP. While routine 
performance of anterior biopsies was shown to be not warranted, anterior biopsies have 
been recommended as part of repeat extended field biopsies [32]. Liu et al. evaluated 116 
patients who underwent sextant plus transition zone biopsies after prior negative sextant 
biopsies [42]. Overall, 36 (31.0%) were found to have prostate cancer while 11 (9.5%) 
demonstrated cancer only in the transition zone. Most investigators suggest 2 cores 
bilaterally from the transition zone while others recommend 3 biopsies from each side of the 
prostate in an anterior version of the sextant biopsy scheme [32, 39]. Adjusting the number 
of anterior biopsies according to the size of the transition zone, spacing them approximately 
1cm apart, has also been suggested [43].  
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Transition zone biopsies should be performed near the midline, as close as possible to the 
urethra and anterior fibromuscular stroma. Transition zone biopsies are taken by advancing 
the biopsy needle through the posterior capsule of the prostate, into the peripheral zone to 
within 2-3 mm of the sonographically evident surgical capsule between the transition zone 
and the peripheral zone before firing; in prostates that extend far anteriorly (determined by 
the anteroposterior dimension of the transition zone exceeding 2cm), the needle is advanced 
through the surgical capsule and into the transition zone in order to sample the anterior-
most tissue where transition zone tumors most frequently reside [41].  
Midline biopsies 
Performance of biopsies in the midline of the prostate has been utilized by some authors 
[37]. These biopsies have a very low yield compared to sextant, anterior, or lateral biopsies 
and have not been widely accepted by other investigators [38]. Even proponents of routinely 
performed extended field biopsies, find that these midline cores provide the least additional 
information [39,40].  
Anterior apical biopsies 
The entire apex of the prostate is composed of peripheral zone where it wraps around the 
caudal extent of the transition zone Although extended biopsy schemes sample the posterior 
and lateral apex, the anterior apex of the prostate is potentially undersampled. Several 
investigators have independently recommended that additional cores should be taken from 
the anterior apex on repeat biopsy [16, 44, 45]. 
Saturation biopsies 
One of the most aggressive biopsy approaches suggested in patients with prior negative 
biopsies is the “saturation biopsy” technique [46]. The approach was originally described as 
multiple cores take from each of the 12 midlobe and lateral sextant locations as well as the 
transition zone. A mean of 23 cores were performed under anesthesia as an outpatient 
procedure. Subsequent use of a 24-core office-based saturation biopsy approach was described 
by Jones et al [47]. The utility of saturation biopsies for initial biopsies has been shown to be 
limited but use as a repeat biopsy scheme, with or without anesthesia may have a role in some 
patients [23, 48]. In patients who did not tolerate their initial biopsies without anesthesia very 
well, proceeding with performance of saturation biopsy under anesthesia rather than repeat, 
less extensive biopsies without anesthesia is often the more humane option. 
Transperineal template biopsies 
Igel et al. advocate employing the transperineal template apparatus used for brachytherapy 
seed implants for extensive repeat biopsy sampling [49]. In there follow-up study in which 
over 80% of patients had had at least 2 prior transrectal biopsy procedures, cancer was 
detected in 37% of patients [50]. The method seems to be superior in sampling the transition 
zone as 77% of the cancers in these patients with prior negative transrectal biopsies had 
cancer in the transition zone biopsies. Some experts question the accuracy of the assumed 
location of biopsy placement by this method [16]. 
How many repeat biopsy sessions is enough? 
Unfortunately, negative repeat biopsies do not often settle the question of the presence or 
absence of prostate cancer. Multiple repeat biopsy procedures that reveal no cancer despite 
a rising PSA cause increasing frustration for the patient and urologist, alike. In men with 
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serum PSA levels between 4 and 10ng/ml, the European Randomized Study for Screening 
for Prostate Cancer demonstrated cancer detection rates on biopsies 1, 2, 3 and 4 of 22% (231 
out of 1051), 10% (83 of 820), 5% (36 of 737) and 4% (4 out of 94), respectively [2]. The 
pathological and biochemical features of cancers detected on the first two sets of biopsies 
were similar but cancers detected on the third and fourth sets had lower grade, stage and 
volume. Even before the widespread use of extended biopsy protocols, a significant 
decreased yield after the third set of biopsies was demonstrated [1]. Therefore, after 2 or 3 
sets of negative biopsies, further repeat biopsies appeared to be justified in very young, 
healthy patients where there is a very high suspicion of cancer despite two sets of negative 
findings [2]. Resnick et al. noted the risk of clinically insignificant disease in those patients 
diagnosed with prostate cancer on first repeat biopsy, on second repeat biopsy, and on third 
repeat biopsy of 31.1%, 43.8%, and 46.8%, respectively (p<0.01) (54). Conversely, the risk of 
adverse pathology in the above groups was determined to be 64.6%, 53.0%, and 52.0%, 
respectively (p<0.01) (54).  
Complications of repeat prostate biopsy 
Prostate biopsy is not entirely free from morbidity, especially in the setting of serial biopsies. 
In a cohort of greater than 75,000 patients, Nam et al. reported that the risk of post-biopsy 
hospital admission rates have increased from 1.0% in 1996 to 4.1% in 2005. There is concern 
for fluoroquinolone resistant infections, and the AUA Best practices statement recommends 
antibiotic prophylaxis.  
In the prospective European Prostate Cancer Detection Study, Djavan et al. report minor or 
no discomfort was observed in 92% and 89% of patients at first and re-biopsy, respectively 
(p _ 0.29). Immediate morbidity was minor and included rectal bleeding (2.1% versus 2.4%, 
p _ 0.13), mild hematuria (62% versus 57%, p _ 0.06), severe hematuria (0.7% versus 0.5%, p 
_ 0.09) and moderate to severe vasovagal episodes (2.8% versus 1.4%, respectively, p _ 0.03). 
Delayed morbidity of first and re-biopsy was comprised of fever (2.9% versus 2.3%, p _ 
0.08), hematospermia (9.8% versus 10.2%, p _ 0.1), recurrent mild hematuria (15.9% versus 
16.6%, p _ 0.06), persistent dysuria (7.2% versus 6.8%, p  0.12) and urinary tract infection 
(10.9% versus 11.3%, respectively, p _ 0.07). Major complications were rare and included 
urosepsis (0.1% versus 0%) and rectal bleeding that required intervention (0% versus 0.1%, 
respectively) (59). Hence, repeat biopsy was recommend repeat after 6 weeks with no 
significant difference in pain or morbidity.  
2. Conclusions 
The primary indications for repeat biopsies are a persistently elevated/rising PSA , active 
surveillance protocols, or suspicious histology on initial biopsies. Variations of PSA 
measurement may help determine the need for repeat biopsies. Repeat biopsies should include 
a minimum of 14 cores including parasagittal and lateral sextant biopsies and 2 additional 
cores obtained from the right and left anterior apex. For patients in whom repeat biopsies fail 
to identify cancer despite a high clinical suspicion, consideration for repeat 14-core biopsy with 
additional 4 to 6 transition zone biopsies or a saturation biopsy approach seems warranted. 
Repeat biopsies after 2 or 3 biopsies fail to reveal cancer have limited yield. There is no 
significant increase in morbidity for repeat biopsy procedures after six weeks. 
Further areas of study include determining any difference in the indications for repeat 
biopsy in patients with risk factors such as a family history of prostate cancer or African 
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American patients. Artificial neural networks incorporating the multiple potential indicators 
of repeat biopsies have yet gain the ease of use necessary for routine clinical care but may 
have future utility. Advanced sonographic technological such as power Doppler and 
elastography as well as biopsy needles that provide feedback on tissue characteristics have 
shown some promise. Additionally, transrectal MRI-guidance or MR spectroscopy for 
prostate biopsy have also been performed with promising results. Adjustment of biopsy 
schemes to allow tailoring to individual patient prostate size and shape may also improve 
yield without continued increase in the total number of biopsies performed  
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